2024
DOI: 10.1055/a-2247-4209
|View full text |Cite
|
Sign up to set email alerts
|

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics

Jennifer Gebetsberger,
Werner Streif,
Christof Dame

Abstract: This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pediatric patients. Romiplostim and eltrombopag are already established as second-line treatment for persistent or chronic immune thrombocytopenia (ITP). As in adults, TPO-RAs are currently al… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 99 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?